Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
BMJ Case Rep ; 14(2)2021 02 26.
Article in English | MEDLINE | ID: mdl-33637513

ABSTRACT

A severe case of COVID-19 was observed in an otherwise healthy 28-year-old man who had taken oxandrolone 40 mg/day as an anabolic steroid. The patient had been taking oxandrolone for enhanced bodybuilding 30 days prior to presenting to an outpatient clinic with COVID-19 symptoms. The patient reported that his symptoms have rapidly worsened over the course of 4 days prior to presenting at the clinic. As part of an experimental antiandrogen treatment for hyperandrogenic men suffering from COVID-19, he was administered a single 600 mg dose of the novel antiandrogen proxalutamide. Twenty-four hours after administration of this dose, marked improvement of symptoms and markers of disease severity were observed. To our knowledge, this is the first case that potentially links anabolic steroid use to COVID-19 disease severity.


Subject(s)
Anabolic Agents/adverse effects , Androgen Antagonists/administration & dosage , COVID-19 Drug Treatment , Oxandrolone/adverse effects , Oxazoles/administration & dosage , Thiohydantoins/administration & dosage , Adult , Anabolic Agents/administration & dosage , Disease Progression , Humans , Male , Oxandrolone/administration & dosage , Performance-Enhancing Substances/adverse effects , SARS-CoV-2 , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL